CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics


CNS PHARMACEUTICALS, INC. (CNSP): $0.27

-0.02 (-5.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CNSP Stock Price Chart Interactive Chart >

Price chart for CNSP

CNSP Price/Volume Stats

Current price $0.27 52-week high $1.98
Prev. close $0.28 52-week low $0.25
Day low $0.25 Volume 538,200
Day high $0.28 Avg. volume 1,300,679
50-day MA $0.30 Dividend yield N/A
200-day MA $0.71 Market Cap 10.61M

CNS PHARMACEUTICALS, INC. (CNSP) Company Bio


CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.


CNSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CNSP Latest Social Stream


Loading social stream, please wait...

View Full CNSP Social Stream

Latest CNSP News From Around the Web

Below are the latest news stories about CNS Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNSP as an investment opportunity.

Maxim Group Keeps Their Buy Rating on CNS Pharmaceuticals (CNSP)

In a report issued on February 2, Jason McCarthy from Maxim Group maintained a Buy rating on CNS Pharmaceuticals (CNSP – Research Report), with a price target of $2.00. The company's shares closed last Friday at $0.44, close to its 52-week low of $0.42. According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CNS Pharmaceuticals.

Brian Anderson on TipRanks | February 6, 2022

WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity

Commercially Reasonable Development Expenditures of at least US$2,000,000 going towards the development, testing, regulatory approval or commercialization of the licensed product, Berubicin, during the applicable development periodVANCOUVER, British Columbia, Feb. 01, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), announced that in respect to its sublicense agreement with CNS Pharmaceuticals, Inc. (the “CNS Agreement”) on December 23, 2021, CN

Yahoo | February 1, 2022

CNS Pharmaceuticals (CNSP) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | January 26, 2022

Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?

Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.

Yahoo | January 20, 2022

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will participate in the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 11:00 AM ET.

Yahoo | January 20, 2022

Read More 'CNSP' Stories Here

CNSP Price Returns

1-mo -14.99%
3-mo -20.59%
6-mo -65.03%
1-year -85.16%
3-year N/A
5-year N/A
YTD -61.56%
2021 -60.54%
2020 -54.94%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.459 seconds.